The abstract is read at the publisher; the summary is JClub's.
Psilocybin therapy in people with Parkinson disease and mood dysfunction is assessed for linked changes in systemic inflammation and mitochondrial stress markers.
- Why it matters: In Parkinson disease, systemic inflammation and mitochondrial stress are relevant targets, but the relationship to psilocybin therapy in this specific patient group is unclear.
- What they did: In a nonrandomized clinical trial, psilocybin therapy was evaluated by measuring systemic markers of inflammation and mitochondrial stress before and after treatment in participants with Parkinson disease and mood dysfunction.
- The result: The trial is designed to determine whether psilocybin therapy is associated with changes in these systemic inflammatory and mitochondrial stress markers, informing future research directions.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.